Main Menu
Donate
Sign Up

Autoimmunity and Autoantibodies in ME/CFS

Study AIM

Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls, examine why these autoantibodies start to show up in the disease process and how we might positively impact this process with various drug targets and immune regulatory treatments. Being able to explain these underlying mechanisms may provide the validation needed for specific ongoing treatments.

LEAD INVESTIGATORS
  • Jonas Bergquist, MD, PhD
  • Annie Bynke, Med Student, PhD
  • Per Julin, MD, PhD
  • CG Gottfries, MD, PhD
  • Carmen Scheibenbogen, MD, PhD
Updates and Potential
STUDY HYPOTHESIS AND DESCRIPTION

The development of autoimmune antibodies is a consistent finding across HSE, ME/CFS, Long COVID and provide a window into the neurocognitive disturbances, peripheral symptoms, POTS, pain, and other targets of these autoantibodies.

Previously, autoantibodies have been observed to have increased binding to adrenergic and muscarinic receptors in ME/CFS patients. It is hypothesized

that these autoantibodies may be part of the pathogenesis of ME/CFS and patient symptom.

OBJECTIVES

  • Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls.
  • Combine these findings with ME/CFS patients and contrast groups (including such as Long COVID, critical COVID patients, neuroimmunology induced cognitive dysfunction patients).
  • Evaluate data to identify potential differences and patient subgroups.

 

Other links you might be interested in:

Collaborative Research Center Stanford
Computational Research Center for Complex Diseases
Facebook Twitter Youtube Instagram Linkedin

OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.

2024 YEAR END REPORT

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2025 Open Medicine Foundation. All Rights Reserved.


Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
Give now from your
Donor-Advised Fund
 
Donate